88
Participants
Start Date
April 4, 2019
Primary Completion Date
January 6, 2025
Study Completion Date
January 6, 2025
Darleukin
The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
Radiation
Radiotherapy
UCL St. Luc, Brussels
UZ Gent, Ghent
UZ Leuven, Leuven
GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk
Centre Oscar Lambret Lille, Lille
INSTITUT régional du CANCER MONTPELLIER - ICM - VAL d'AURELLE, Montpellier
University Hospital Carl Gustav Carus, Dresden
Klinikum der Universität Heidelberg, Heidelberg
University Hospital Tübingen, Tübingen
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome
AVL-NKI, Amsterdam
Radboud UMC Nijmegen, Nijmegen
Erasmus MC, Rotterdam
University College London Hospital, London
Academisch Ziekenhuis Maastricht (Leading Centre), Maastricht
Collaborators (1)
Academisch Ziekenhuis Maastricht
OTHER
The Netherlands Cancer Institute
OTHER
University Medical Center Nijmegen
OTHER
Erasmus Medical Center
OTHER
University Ghent
OTHER
KU Leuven
OTHER
Centre Oscar Lambret
OTHER
Gasthuis Zusters Antwerpen
OTHER
University College, London
OTHER
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
University Hospital Dresden
OTHER
University Hospital Tuebingen
OTHER
Heidelberg University
OTHER
Catholic University of the Sacred Heart
OTHER
Institut du Cancer de Montpellier - Val d'Aurelle
OTHER
Maastricht University Medical Center
OTHER